Hikal Limited
HIKAL.NS
Get informed when a big investor buys or sells
+ FollowMarket Cap$26.34B
Close$
$-14.41
106.7% downside
Current Fair Value
106.7% downsideOvervalued by 106.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $26.34 Billion |
|---|---|
| Enterprise Value | $26.34 Billion |
| Dividend Yield | $0.60 (0.28%) |
| Earnings per Share | $-3.96 |
| Beta | 1.61 |
| Outstanding Shares | 123,300,750 |
Return
| Return on Equity | -2.82% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -77.98 |
|---|---|
| PEG | 116.45 |
| Price to Sales | 1.55 |
| Price to Book Ratio | 2.23 |
| Enterprise Value to Revenue | 1.52 |
| Enterprise Value to EBIT | 99.04 |
| Enterprise Value to Net Income | -78 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$4.10 B
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$3.88 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Hikal Limited
2,208 employees
CEO: Sameer Hiremath Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and...